Outsourced AstraZeneca blockade not an issue for local COVID vaccine rollout

EU's decision to block 250,000 doses of AstraZeneca vaccine to Australia not an issue for covid vaccine rollout thanks to CSL local production

| More on:
CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Countries are holding on tight to their locally produced COVID-19 vaccines. As reported by ABC News, Italy and the European Union pulled the handbrake on the 250,000 AstraZeneca Plc (LSE: AZN) doses bound for Aussie shores. Australian politicians have stated that this is not an issue for our COVID-19 vaccine rollout.

As countries globally rush to get their hands on an approved vaccine, tensions have developed. Considering it is a potential ticket to returned economic growth, some are prioritising their own jurisdictions first and foremost.

Not an issue for our vaccine rollout

Australian Health Minister Greg Hunt remarked that this decision by the EU would not impact Australia's COVID vaccine rollout:

This is one shipment from one country. This shipment was not factored into our distribution plan for the coming weeks. Domestic production starts with 1 million per week of deliveries from late March and is on track.

NSW Premier Gladys Berejiklian commented on the news this morning, emphasising the critical nature of local production:

I think what it demonstrates is the importance of us having a local supply. In the future, there will be supply issues. You need lots of jabs to be vaccinated properly, and therefore it's really important for us to be able to have our local supply.

The local supply these ministers refer to is coming from Australian-based CSL Ltd (ASX: CSL). Despite the emphasised importance of its operations this morning, the CSL share price is trending 2.6% lower. The biotech giant has now fallen for four consecutive sessions, erasing 8% in 4 days.

Domestic production of the AstraZeneca vaccine by CSL was expected to begin in early March. The company's production is anticipated to yield around 1 million doses per week by the end of March.

Ironic timing as first AstraZeneca vaccine administered

The EU's decision to block the 250,000 vaccines comes at an ironic time, as the first AstraZeneca dose was administered in Australia today.

An estimated 40 frontline staff at the Murray Bridge Hospital in South Australia will have received the vaccine by the end of the day.

Premier Berejiklian also mentioned that she believed media coverage should pivot to reporting on the number of vaccines administered rather than the number of new cases.

Furthermore, with the COVID vaccine rollout underway, the premier urged for the reopening of borders. Otherwise, she said, Australia could be left in the dust economically.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A couple sit in front of a laptop reading ASX shares news articles and learning about ASX 200 bargain buys
Share Market News

Ampol delivers $649m RCOP EBITDA and updates investors on strategic growth

Ampol delivers $649m RCOP EBITDA for 1H 2025 and details growth plans as it advances the EG Australia acquisition.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Share Market News

GQG Partners share price in focus after November FUM update

GQG Partners shares are in the spotlight as the fund manager posts a US$166.1bn FUM update for November 2025.

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Share Market News

Ramelius Resources launches share buy-back: What investors need to know

Ramelius Resources is set to buy back up to 73.96 million shares on-market between December 2025 and June 2027.

Read more »

A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
Broker Notes

These ASX 200 shares could rise 30% to 40%

Looking for big returns? Bell Potter thinks these shares could be the ones to buy.

Read more »

man in old fashioned suit and hat looking through magnifying glass
Blue Chip Shares

Is the CSL share price a generational bargain at $180?

CSL shares are currently trading near a 7-year low.

Read more »

A young man in a blue suit sits on his desk cross-legged with his phone in his hand looking slightly crazed.
Share Market News

3 ASX shares down 20% to 40% in 2025: Why analysts say you should hold on

These 3 ASX All Ords shares are among 174 out of 500 that have experienced share price falls this year.

Read more »

A kid wearing a pilot helmet holds a paper plane up to the sky.
Share Market News

Own ANZ shares? Here are the dividend dates for 2026

ANZ shares have risen faster than the other big four bank stocks in 2025.

Read more »

Man standing on the roof rack of a van next to boxes and gear
Broker Notes

Broker tips 30% upside for this ASX 200 stock

This ASX 200 stock could now be a buy-low option.

Read more »